Next 10 |
2024-05-10 16:30:03 ET Oppenheimer analyst issues MARKET OUTPERFORM recommendation for RLAY on May 10, 2024 02:00PM ET. The previous analyst recommendation was Market Outperform. RLAY was trading at $6.425 at issue of the analyst recommendation. The overall analyst conse...
2024-05-10 11:13:46 ET More on Relay Therapeutics Relay Therapeutics: Platform More Important Than Programs Relay Therapeutics: Tapping Into An Unmet Need At A High Price Tag Relay Therapeutics GAAP EPS of -$0.62 beats by $0.10, revenue of $10.01M beats by $9.09M ...
2024-05-06 09:15:03 ET Oppenheimer analyst issues OUTPERFORM recommendation for RLAY on May 6, 2024 07:53AM ET. The previous analyst recommendation was Outperform. RLAY was trading at $7.04 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-05-03 01:41:11 ET More on Relay Therapeutics Relay Therapeutics: Platform More Important Than Programs Relay Therapeutics: Tapping Into An Unmet Need At A High Price Tag Seeking Alpha’s Quant Rating on Relay Therapeutics Historical earnings data f...
2024-05-02 16:25:12 ET More on Relay Therapeutics Relay Therapeutics: Platform More Important Than Programs Relay Therapeutics: Tapping Into An Unmet Need At A High Price Tag Seeking Alpha’s Quant Rating on Relay Therapeutics Historical earnings data f...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported first quarter 2024 financia...
CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report first quarter 2024 financial res...
2024-04-24 06:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-14 08:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will partici...
News, Short Squeeze, Breakout and More Instantly...
Relay Therapeutics Inc. Company Name:
RLAY Stock Symbol:
NASDAQ Market:
2024-05-10 16:30:03 ET Oppenheimer analyst issues MARKET OUTPERFORM recommendation for RLAY on May 10, 2024 02:00PM ET. The previous analyst recommendation was Market Outperform. RLAY was trading at $6.425 at issue of the analyst recommendation. The overall analyst conse...
2024-05-06 09:15:03 ET Oppenheimer analyst issues OUTPERFORM recommendation for RLAY on May 6, 2024 07:53AM ET. The previous analyst recommendation was Outperform. RLAY was trading at $7.04 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported first quarter 2024 financia...